229 related articles for article (PubMed ID: 9820739)
21. Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines.
Sun C; Yamato T; Furukawa T; Ohnishi Y; Kijima H; Horii A
Oncol Rep; 2001; 8(1):89-92. PubMed ID: 11115575
[TBL] [Abstract][Full Text] [Related]
22. DCC and SMAD4 alterations in human colorectal and pancreatic tumor dissemination.
Tarafa G; Villanueva A; Farré L; Rodríguez J; Musulén E; Reyes G; Seminago R; Olmedo E; Paules AB; Peinado MA; Bachs O; Capellá G
Oncogene; 2000 Jan; 19(4):546-55. PubMed ID: 10698524
[TBL] [Abstract][Full Text] [Related]
23. Characterization of a newly established human pancreatic carcinoma cell line, UK Pan-1.
Fralix KD; Ahmed MM; Mattingly C; Swiderski C; McGrath PC; Venkatasubbarao K; Kamada N; Mohiuddin M; Strodel WE; Freeman JW
Cancer; 2000 May; 88(9):2010-21. PubMed ID: 10813711
[TBL] [Abstract][Full Text] [Related]
24. Molecular pathogenesis of pancreatic cancer.
Hilgers W; Rosty C; Hahn SA
Hematol Oncol Clin North Am; 2002 Feb; 16(1):17-35, v. PubMed ID: 12063826
[TBL] [Abstract][Full Text] [Related]
25. Fluorescence in situ hybridization as a tool to characterize genetic alterations in pancreatic adenocarcinoma.
Genevay M; Dumonceau JM; Pepey B; Pache JC; Rubbia-Brandt L; McKee TA
Pancreas; 2010 May; 39(4):543-4. PubMed ID: 20418759
[No Abstract] [Full Text] [Related]
26. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.
Kawesha A; Ghaneh P; Andrén-Sandberg A; Ograed D; Skar R; Dawiskiba S; Evans JD; Campbell F; Lemoine N; Neoptolemos JP
Int J Cancer; 2000 Nov; 89(6):469-74. PubMed ID: 11102889
[TBL] [Abstract][Full Text] [Related]
27. K-ras, p53, and DPC4 (MAD4) alterations in fine-needle aspirates of the pancreas: a molecular panel correlates with and supplements cytologic diagnosis.
van Heek T; Rader AE; Offerhaus GJ; McCarthy DM; Goggins M; Hruban RH; Wilentz RE
Am J Clin Pathol; 2002 May; 117(5):755-65. PubMed ID: 12090425
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
[TBL] [Abstract][Full Text] [Related]
29. Pancreatic cancer screening in high-risk individuals with germline genetic mutations.
DaVee T; Coronel E; Papafragkakis C; Thaiudom S; Lanke G; Chakinala RC; Nogueras González GM; Bhutani MS; Ross WA; Weston BR; Lee JH
Gastrointest Endosc; 2018 Jun; 87(6):1443-1450. PubMed ID: 29309780
[TBL] [Abstract][Full Text] [Related]
30. The molecular genetics of pancreatic cancer.
Howe JR; Conlon KC
Surg Oncol; 1997; 6(1):1-18. PubMed ID: 9364657
[TBL] [Abstract][Full Text] [Related]
31. Gene therapy and pancreatic cancer.
Pearson AS; Bouvet M; Evans DB; Roth JA
Front Biosci; 1998 Nov; 3():E230-7. PubMed ID: 9792901
[TBL] [Abstract][Full Text] [Related]
32. Molecular genetics of exocrine pancreatic neoplasms.
Hahn SA; Kern SE
Surg Clin North Am; 1995 Oct; 75(5):857-69. PubMed ID: 7660250
[TBL] [Abstract][Full Text] [Related]
33. Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma.
Hua Z; Zhang YC; Hu XM; Jia ZG
World J Gastroenterol; 2003 Dec; 9(12):2764-7. PubMed ID: 14669329
[TBL] [Abstract][Full Text] [Related]
34. Tumor suppressor gene Smad4/DPC4, its downstream target genes, and regulation of cell cycle.
Chiao PJ; Hunt KK; Grau AM; Abramian A; Fleming J; Zhang W; Breslin T; Abbruzzese JL; Evans DB
Ann N Y Acad Sci; 1999 Jun; 880():31-7. PubMed ID: 10415848
[TBL] [Abstract][Full Text] [Related]
35. Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma.
Heinmöller E; Dietmaier W; Zirngibl H; Heinmöller P; Scaringe W; Jauch KW; Hofstädter F; Rüschoff J
Am J Pathol; 2000 Jul; 157(1):83-92. PubMed ID: 10880379
[TBL] [Abstract][Full Text] [Related]
36. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma.
Biankin AV; Morey AL; Lee CS; Kench JG; Biankin SA; Hook HC; Head DR; Hugh TB; Sutherland RL; Henshall SM
J Clin Oncol; 2002 Dec; 20(23):4531-42. PubMed ID: 12454109
[TBL] [Abstract][Full Text] [Related]
37. Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups.
Yan L; McFaul C; Howes N; Leslie J; Lancaster G; Wong T; Threadgold J; Evans J; Gilmore I; Smart H; Lombard M; Neoptolemos J; Greenhalf W
Gastroenterology; 2005 Jun; 128(7):2124-30. PubMed ID: 15940643
[TBL] [Abstract][Full Text] [Related]
38. Cellular and molecular biology of biliary tract cancers.
Rashid A
Surg Oncol Clin N Am; 2002 Oct; 11(4):995-1009. PubMed ID: 12607585
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical study of genetic alterations in intraductal and invasive ductal tumors of the pancreas.
Islam HK; Fujioka Y; Tomidokoro T; Sugiura H; Takahashi T; Kondo S; Katoh H
Hepatogastroenterology; 2001; 48(39):879-83. PubMed ID: 11462947
[TBL] [Abstract][Full Text] [Related]
40. Familial pancreatic cancer and the genetics of pancreatic cancer.
Lumadue JA; Griffin CA; Osman M; Hruban RH
Surg Clin North Am; 1995 Oct; 75(5):845-55. PubMed ID: 7660249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
